Investors

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Stock option plans

Stock option plan 2022/2026

The 2022 AGM resolved to set up a stock option plan, 2022/2026 for employees of Egetis Therapeutics AB for 7,300,000 stock options. In order to secure the delivery of stock options and future estimated social security contributions in conjunction with exercising the options, the Egetis Therapeutics subsidiary, Egetis Therapeutics Incentive AB, subscribed for 9,592,200 warrants.

 

Stock option plan 2021/2025

The 2021 AGM resolved to set up a stock option plan, 2021/2025 for employees of Egetis Therapeutics AB for 5,000,000 stock options. In order to secure the delivery of stock options and future estimated social security contributions in conjunction with exercising the options, the Egetis Therapeutics subsidiary, Egetis Therapeutics Incentive AB, subscribed for 6,571,000 warrants.

 

Stock option plan 2020/2024

The 2020 AGM resolved to set up a stock option plan for employees of Egetis Therapeutics for 3,000,000 stock options. Of that amount, 2,900,000 of the stock options had been allocated to employees as of 31 December 2021.

Each employee stock option entitles the holder to acquire one new share at a price of SEK 12.30. Allotted employee stock options vest for a period from the date of allotment to 7 May 2023. The participant can exercise allotted and vested employee stock options from 7 May 2023 until 7 May 2024. Exercise of employee stock options require that the participant is employed by the company during the whole vesting period. The employee stock options shall not be considered securities and shall not be possible to transfer or pledge. In order to make delivery of shares under the employee stock option program possible, and to secure costs associated therewith, in particular social security contributions, the Annual General Meeting resolved on a directed issue of no more than 3,942,000 warrants and to approve transfer of warrants.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]